Gland Pharma Moat Analysis: Score & Risks
Gland Pharma Ltd.
A first-pass moat teardown of Gland Pharma Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Intangible Assets. Provisional, single-pass evidence.
Gland Pharma Ltd. scores 5.37 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Acquiring Cenexi gives us access to knowhow and development capabilities in sterile forms, including for ophthalmic gel, needleless injectors and hormones.”
“New high-capacity ampoule line is being added, with a capacity of 30 million by 2027, strengthening the position of the site on the market as the largest ampoule manufacturing site in Europe”
“we're trying to grow substantially, but not at kind of products, more complex specialty kind of products”
“Our B2B business model allows us to leverage our relationship with customers to efficiently reach end-users.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6.0 — clears the gate. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 113 Indian companies we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: Wide-Moat Stocks in India: We Scored 113 Companies and Found None. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion